Virbac Posts Strong H1 2026 Growth on Supercharge Platforms

Event summary

H1 2026 revenue reached €768m, up +7.4% at CERS vs H1 2025.
Companion animal segment grew +10.0%, farm animal +6.7%, driven by Supercharge platforms (+12% CERS).
Thyronorm acquisition contributed 1.4 percentage points to overall growth.
North America saw double-digit growth despite temporary manufacturing challenges.
Full-year guidance confirmed at upper end of 5.5%-7.5% revenue growth range.

The big picture

Virbac's strong H1 performance reflects robust demand in both companion and farm animal segments, particularly through its Supercharge platforms targeting high-unmet needs. The company's ability to navigate currency headwinds and temporary operational disruptions will be key as it aims for the upper end of its full-year guidance range. With €768m in H1 revenue, Virbac is positioning itself as a leader in the growing animal healthcare sector.

What we're watching

Geographic Expansion: Whether Virbac can sustain double-digit growth in North America and International regions despite currency headwinds.
Operational Challenges: How temporary manufacturing issues will impact Q3 performance after July 2026 resumption.
Integration Success: The pace at which Thyronorm acquisition synergies materialize across multiple continents.